News

MARCH 20, 2017:

AvantBio’s (AvantFluor’s) patent application regarding its new Sulfur Fluoride (SF4, SF5Cl, SF5Cl, SF6) production processes has recently been granted in India, in addition to South Korea, Canada, Japan, China, the Russian Federation, Mexico, Australia and South Africa.  Patent allowances are also expected in the European Federation and the United States.  With the addition of India to our patent-protected jurisdictions, AvantBio (AvantFluor)  can now effectively operate in both the Asian and some of the North American markets. It is expected that AvantBio’s new Sulfur Fluoride production processes may significantly reduce the cost of bringing  AvantBio’s “C-F” (SF4) and “C-SF5” (SF5Cl, SF5Br) fluorinating reagents into the marketplace. With the advent of less costly and more routinely available SF5Cl and SF5Br, less costly downstream aliphatic R-SF5  derivatives are also expected to become more readily-available  as well.  (click here for more information and business development opportunities).

DECEMBER 10, 2016:

AvantBio’s (AvantFluor’s) patent application regarding its new Sulfur Pentafluorobromide (SF5Br) production process has recently been granted in Canada, in addition to Japan, South Korea, China, the Russian Federation, Mexico, Australia and South Africa. AvantBio (AvantFluor)  anticipates patent allowances in the European Federation, the United States and India as well.  With the addition of Canada to the list of patent-protected jurisdictions, AvantBio (AvantFluor)  can now operate in both the Asian and some of the North American markets. It is expected that AvantBio’s new Sulfur Fluoride production processes may significantly reduce the cost of bringing  AvantBio’s “C-F” (SF4) and “C-SF5” (SF5Cl, SF5Br) fluorinating reagents into the marketplace. With the advent of less costly and more routinely available SF5Cl and SF5Br, less costly downstream aliphatic R-SF5  derivatives are also expected to become more readily-available  as well.  (click here for more information and business development opportunities).

March 4, 2016

AvantBio’s (AvantFluor’s) patent application regarding its new Sulfur Fluoride (SF4, SF5Cl, SF5Cl, SF6) production processes has recently been granted in South Korea, in addition to Canada, Japan, China, the Russian Federation, Mexico, Australia and South Africa.  Patent allowances are also expected in the European Federation, the United States and India.  With the addition of South Korea to our patent-protected jurisdictions, AvantBio (AvantFluor)  can now effectively operate in both the Asian and some of the North American markets. It is expected that AvantBio’s new Sulfur Fluoride production processes may significantly reduce the cost of bringing  AvantBio’s “C-F” (SF4) and “C-SF5” (SF5Cl, SF5Br) fluorinating reagents into the marketplace. With the advent of less costly and more routinely available SF5Cl and SF5Br, less costly downstream aliphatic R-SF5  derivatives are also expected to become more readily-available  as well.  (click here for more information and business development opportunities).

October 30, 2015

AvantBio’s (AvantFluor’s) patent application regarding its new Sulfur Fluoride (SF4, SF5Cl) production processes has recently been granted in Canada, in addition to Japan, China, the Russian Federation, Mexico, Australia and South Africa. AvantBio (AvantFluor)  anticipates patent allowances in the European Federation, South Korea, the United States and India as well.  With the addition of Canada to the list of patent-protected jurisdictions, AvantBio (AvantFluor)  can now operate in both the Asian and some of the North American markets. It is expected that AvantBio’s new Sulfur Fluoride production processes may significantly reduce the cost of bringing  AvantBio’s “C-F” (SF4) and “C-SF5” (SF5Cl, SF5Br) fluorinating reagents into the marketplace. With the advent of less costly and more routinely available SF5Cl and SF5Br, less costly downstream aliphatic R-SF5  derivatives are also expected to become more readily-available  as well.  (click here for more information and business development opportunities).

July 15, 2015

AvantBio’s (AvantFluor’s) patent application regarding its new Sulfur Fluoride (SF4, SF5Cl, SF5Br and SF6) production processes has recently been granted in Japan, in addition to China, the Russian Federation, Mexico, Australia and South Africa. Dr. Rolf Winter (Inventor, VP and Director of Chemistry Research) and Dr. Paul W. Cook (President and CSO) anticipate future patent approvals in the European Federation, Canada, South Korea, the United States and India.  With the addition of Japan to the list of patent-protected jurisdictions, AvantBio (AvantFluor)  should be able to now readily operate in the Asian markets. It is expected that AvantBio’s new Sulfur Fluoride production processes may significantly reduce the cost of bringing  AvantBio’s “C-F” (SF4) and “C-SF5” (SF5Cl, SF5Br) fluorinating reagents into the marketplace. With the advent of less costly and more routinely available SF5Cl and SF5Br, less costly downstream aliphatic R-SF5  derivatives are also expected to become more readily-available  as well.  (click here for more information and business development opportunities).

July 12, 2015

AvantBio’s (AvantFluor’s) patent application regarding its new Sulfur Fluoride (SF4, SF5Cl, SF5Br and SF6) production processes has recently been granted in China, in addition to the Russian Federation, Mexico, Australia and South Africa. Dr. Rolf Winter (Inventor, VP and Director of Chemistry Research) and Dr. Paul W. Cook (President and CSO) anticipate future patent approvals in Japan, the European Federation, Canada, South Korea, the United States and India.  It is expected that AvantBio’s new Sulfur Fluoride production processes may significantly reduce the cost of bringing  AvantBio’s “C-F” (SF4) and “C-SF5” (SF5Cl, SF5Br) fluorinating reagents into the marketplace. With the advent of less costly and more routinely available SF5Cl and SF5Br, less costly downstream aliphatic R-SF5  derivatives are also expected to become more readily-available  as well.  (click here for more information and business development opportunities).

September 20, 2013

AvantBio’s (AvantFluor’s) patent applications regarding its new Sulfur Fluoride production processes have been granted in the Russian Federation, Mexico, Australia and South Africa. Dr. Rolf Winter (Inventor, VP and Director of Chemistry Research) and Dr. Paul W. Cook (President and CSO) anticipate that the these granted patents represent  a harbinger of future patent protection  for AvantBio’s novel Sulfur Fluoride production processes in other  jurisdictions, which include USA, China, Japan, South Korea, Europe and Canada.  (click here for more information on AvantBio’s Sulfur Fluoride technology)

October 4, 2012

AvantBio presents its new and improved defined animal / human origin-free cell (dAOF) cell culture supplement system for human corneal epithelial cells and human corneal fibroblasts (keratocytes) at the European Tissue Repair Society Society (ETRS) 22nd Meeting in Athens, Greece.  Poster AA19: A new cell culture system for the defined, animal origin-free primary isolation and serial propagation of adult human corneal epithelial cells and adult human corneal fibroblasts. Paul W. Cook, Rolf W. Winter and Jeffrey R. Brown.  (click here to view abstract)

May 9, 2012

AvantBio presents its new and improved defined animal / human origin-free cell (dAOF) cell culture supplement system for human keratinocytes and fibroblasts at the annual Society for Investigative Dermatology (SID), 72nd Annual Meeting in Raleigh, North Carolina.  Poster 853: “Improved, defined, animal origin-free (dAOF) primary isolation and serial propagation of human keratinocytes, human corneal epithelial cells and other clinically-relevant cell types.”  Paul W Cook, Rolf W Winter and Jeffrey R Brown. (click here to view abstract)

 

.

February 3, 2012

Using its novel defined animal / human origin-free cell (dAOF) cell culture supplement platform, AvantBio now reports that it has successfully adapted its proprietary  dAOF culture system for the efficient propagation of both human dermal fibroblasts (HDF) and human corneal fibroblasts (Keratocytes).  AvantBio’s new dAOF supplement system performs favorably when compared to supplements which utilize animal-derived serum (FBS).  These recent  results may foster the safer therapeutic treatment of damaged or defective human skin with HDFs cultured in the dAOF environment (e.g. treatment of facial wrinkling), or engineered full-thickness skin that is synthesized ex vivo, using HDFs cultured under complete dAOF culture conditions (e.g. treatment of chronic wounds and burns)

Click here for more information on AvantBio’s dAOF Fibroblast Cell Culture Supplement